Phenotypic and molecular characteristics of nasal mucosal gamma delta T cells in allergic and infectious rhinitis.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Phenotypic and molecular characteristics of nasal mucosal gamma delta T cells in allergic and infectious rhinitis.

Am J Respir Crit Care Med. 1996 May;153(5):1655-65. Unique Identifier : AIDSLINE MED/96210216
Pawankar RU; Okuda M; Suzuki K; Okumura K; Ra C; Department of Otolaryngology, Nippon Medical School, Japan.

Abstract: T cells expressing the T-cell receptor (TCR) gamma delta home in on various epithelia and may play an important role in local immunity to foreign antigens. The nasal mucosa is a potential site for chronic inflammatory diseases, yet little is known about the characteristics of nasal mucosal gamma delta T cells. Using flow cytometry, immunohistochemistry, and RT-PCR, we elucidated the characteristics of nasal mucosal gamma delta T cells in patients with perennial allergic rhinitis (PAR), chronic infective rhinitis (CIR), and seasonal allergic rhinitis (SAR) and in normal subjects. The gamma delta T cells were significantly increased in the nasal mucosa of patients with PAR (PAR, 24.3 +/- 4.5%; CIR, 12.9+/- 2.7%, p < 0.01), unrelated to those in autologous peripheral blood (PAR, 5.6 +/- 0.8%; CIR, 9.6 +/- 2.8%), and they were preferentially distributed in the epithelial compartment (26.7 +/- 2.3%) rather than in the lamina propria (5.4 +/- 2.5%). Of the expanded population of nasal mucosal gamma delta T cells in patients with PAR, CD4+ and CD4-8- gamma delta T cells were selectively increased (p < 0.01). Although nasal intraepithelial gamma delta T cells from all groups of patients and normal subjects dominantly expressed the V gamma 1/V delta 1 genes, and a bias for V gamma 3 gene expression was noted in those of patients with PAR, a significantly larger fraction of nasal mucosal gamma delta T cells in patients with PAR expressed the V gamma 1/V delta 1 TCR (p, 0.01), whereas those of the peripheral blood expressed the V gamma 2/V delta 2 TCR. More than 60% of V gamma 1/V delta 1 TCR+ cells in patients with PAR, were CD45RO+ (memory cells), independent of those in their peripheral blood (p < 0.01). Furthermore, a substantial proportion of nasal mucosal gamma delta T cells in patients with PAR synthesized IL-4 and IL-5 but negligible amounts of IFN-gamma. These observations of an increase in the proportions and activation of distinct subsets of nasal mucosal gamma delta T cells and their Th2-type cytokine profile in patients with PAR, unrelated to those in autologous peripheral blood suggest an important role for the oligoclonally expanded expanded nasal mucosal gamma delta T cells in the pathogenesis of PAR.

Keywords: Adult Chronic Disease CD4-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY/PATHOLOGY Epithelium/IMMUNOLOGY/PATHOLOGY Female Flow Cytometry Fluorescent Antibody Technique, Direct Gene Expression Regulation Hay Fever/BLOOD/IMMUNOLOGY/*PATHOLOGY Human Immunologic Memory Interferon Type II/METABOLISM Interleukin-4/METABOLISM Interleukin-5/METABOLISM Male Molecular Biology Nasal Mucosa/IMMUNOLOGY/*PATHOLOGY Phenotype Polymerase Chain Reaction Receptors, Antigen, T-Cell, gamma-delta/*ANALYSIS/GENETICS Rhinitis/BLOOD/IMMUNOLOGY/*MICROBIOLOGY/PATHOLOGY Rhinitis, Allergic, Perennial/BLOOD/IMMUNOLOGY/*PATHOLOGY Support, Non-U.S. Gov't T-Lymphocyte Subsets/IMMUNOLOGY/*PATHOLOGY Th2 Cells/PATHOLOGY Transcription, Genetic JOURNAL ARTICLE
960930
M9690934

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .